DOI QR코드

DOI QR Code

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma

  • Park, Jongmoo (Department of Radiation Oncology, School of Medicine, Kyungpook National University) ;
  • Park, Jae Won (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kang, Min Kyu (Department of Radiation Oncology, School of Medicine, Kyungpook National University)
  • Received : 2019.07.03
  • Accepted : 2019.07.30
  • Published : 2019.09.30

Abstract

Stereotactic body radiotherapy (SBRT) is an advanced form of radiotherapy (RT) with a growing interest on its application in the treatment of hepatocellular carcinoma (HCC). It can deliver ablative radiation doses to tumors in a few fractions without excessive doses to normal tissues, with the help of advanced modern RT and imaging technologies. Currently, SBRT is recommended as an alternative to curative treatments, such as surgery and radiofrequency ablation. This review discusses the current status of SBRT to aid in the decision making on how it is incorporated into the HCC management.

References

  1. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-16. https://doi.org/10.4143/crt.2018.143
  2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. https://doi.org/10.1016/j.jhep.2006.05.013
  3. Ock M, Choi WJ, Jo MW. Trend analysis of major cancer statistics according to sex and severity levels in Korea. PLoS One 2018;13:e0203110 https://doi.org/10.1371/journal.pone.0203110
  4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019
  5. Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular Carcinoma. Gut Liver 2019;13:227-99. https://doi.org/10.5009/gnl19024
  6. Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol 2008;14:3452-60. https://doi.org/10.3748/wjg.14.3452
  7. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011;98:1210-24. https://doi.org/10.1002/bjs.7669
  8. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078-101. https://doi.org/10.1118/1.3438081
  9. Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol 2019;131:135-44. https://doi.org/10.1016/j.radonc.2018.12.005
  10. Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv238-55. https://doi.org/10.1093/annonc/mdy308
  11. Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2017;27:247-55. https://doi.org/10.1016/j.semradonc.2017.02.002
  12. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 2013;8:e79854 https://doi.org/10.1371/journal.pone.0079854
  13. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-404. https://doi.org/10.3109/0284186X.2013.820342
  14. Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014;20:3100-11. https://doi.org/10.3748/wjg.v20.i12.3100
  15. Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, Lawrence TS, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1410-21. https://doi.org/10.1016/S0360-3016(01)02653-0
  16. Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys 2000;46:329-35. https://doi.org/10.1016/S0360-3016(99)00413-7
  17. Brock KK. Imaging and image-guided radiation therapy in liver cancer. Semin Radiat Oncol 2011;21:247-55. https://doi.org/10.1016/j.semradonc.2011.05.001
  18. Park SH, Kim JC, Kang MK. Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol 2016;22:7311-21. https://doi.org/10.3748/wjg.v22.i32.7311
  19. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015;141:1301-9. https://doi.org/10.1007/s00432-015-1929-y
  20. Lee KH, Yu JI, Park HC, Park SY, Shin JS, Shin EH, et al. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? Radiat Oncol J 2018;36:129-38. https://doi.org/10.3857/roj.2017.00598
  21. Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013;8:250. https://doi.org/10.1186/1748-717X-8-250
  22. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 2011;81:1039-45. https://doi.org/10.1016/j.ijrobp.2010.07.015
  23. Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer 2017;123:3955-65. https://doi.org/10.1002/cncr.30816
  24. Toramatsu C, Katoh N, Shimizu S, Nihongi H, Matsuura T, Takao S, et al. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol 2013;8:48. https://doi.org/10.1186/1748-717X-8-48
  25. Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol 2015;5:209-18. https://doi.org/10.1016/j.prro.2015.01.004
  26. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861-70. https://doi.org/10.3109/02841869509127197
  27. Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, et al. Comparison of percutaneous radiofrequency ablation and $CyberKnife^{(R)}$ for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol 2015;21:13490-9. https://doi.org/10.3748/wjg.v21.i48.13490
  28. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.
  29. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9. https://doi.org/10.1200/JCO.2012.44.1659
  30. Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics 2003;23:123-34. https://doi.org/10.1148/rg.231025054
  31. Rice SL, Bale R, Breen DJ, de Baere T, Denys A, Guiu B, et al. The management of colorectal cancer liver metastases: the interventional radiology viewpoint. Int J Radiat Oncol Biol Phys 2019;103:537-9. https://doi.org/10.1016/j.ijrobp.2018.08.069
  32. Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, et al. Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration. Sci Rep 2018;8:16224. https://doi.org/10.1038/s41598-018-34676-1
  33. Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J Clin Oncol 2018;36:600-8.
  34. Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, et al. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: a propensity-matched analysis in a single institution. Surgery 2018;164:219-26. https://doi.org/10.1016/j.surg.2018.03.006
  35. Su TS, Liang P, Liang J, Lu HZ, Jiang HY, Cheng T, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017;98:639-46. https://doi.org/10.1016/j.ijrobp.2017.02.095
  36. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-100. https://doi.org/10.1016/j.ijrobp.2009.06.092
  37. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006;65:426-34. https://doi.org/10.1016/j.ijrobp.2005.12.031
  38. Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 2013;8:249. https://doi.org/10.1186/1748-717X-8-249
  39. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7. https://doi.org/10.1016/j.radonc.2014.05.002
  40. Su TS, Liang P, Lu HZ, Liang J, Gao YC, Zhou Y, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 2016;113:181-7. https://doi.org/10.1002/jso.24128
  41. Dawson LA. Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011;21:241-6. https://doi.org/10.1016/j.semradonc.2011.05.009
  42. Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S101-7. https://doi.org/10.1016/j.ijrobp.2009.05.071
  43. Bae SH, Kim MS, Kim SY, Jang WI, Cho CK, Yoo HJ, et al. Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies. Int J Colorectal Dis 2013;28:1707-13. https://doi.org/10.1007/s00384-013-1717-6
  44. LaCouture TA, Xue J, Subedi G, Xu Q, Lee JT, Kubicek G, et al. Small bowel dose tolerance for stereotactic body radiation therapy. Semin Radiat Oncol 2016;26:157-64. https://doi.org/10.1016/j.semradonc.2015.11.009
  45. Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dose-volume histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat Oncol 2016;26:149-56. https://doi.org/10.1016/j.semradonc.2015.12.002
  46. Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, et al. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 2015;56:561-7. https://doi.org/10.1093/jrr/rru130
  47. Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018;100:122-30. https://doi.org/10.1016/j.ijrobp.2017.09.001
  48. Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer 2018;18:416. https://doi.org/10.1186/s12885-018-4340-7
  49. Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 2013;85:1006-11. https://doi.org/10.1016/j.ijrobp.2012.09.012
  50. Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC, et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother Oncol 2017;122:130-6. https://doi.org/10.1016/j.radonc.2016.10.024
  51. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-54. https://doi.org/10.1002/lt.23439
  52. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-53. https://doi.org/10.1016/j.ijrobp.2011.04.011
  53. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9. https://doi.org/10.1016/j.jhep.2017.02.022
  54. Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol 2015;1:35-42.
  55. Kim JY, Chung SM, Choi BO, Kay CS. Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy. Hepatol Res 2011;41:813-24. https://doi.org/10.1111/j.1872-034X.2011.00826.x
  56. Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int 2017;37:90-100.
  57. Bae SH, Kim MS, Jang WI, Kim JH, Kim WC, Kim JH, et al. Multicenter planning comparison of stereotactic body radiotherapy for hepatocellular carcinoma with major portal vein tumor thrombosis (KROG 16-17). J Liver Cancer 2018;18:130-41. https://doi.org/10.17998/jlc.18.2.130
  58. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864 https://doi.org/10.1371/journal.pone.0063864
  59. Kang J, Nie Q, DU R, Zhang L, Zhang J, Li Q, et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol 2014;2:43-50. https://doi.org/10.3892/mco.2013.196
  60. Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188. https://doi.org/10.1186/s13014-018-1136-5
  61. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-94. https://doi.org/10.1016/j.radonc.2008.11.002
  62. Jacob R, Turley F, Redden DT, Saddekni S, Aal AK, Keene K, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of $\geq$3 cm. HPB (Oxford) 2015;17:140-9. https://doi.org/10.1111/hpb.12331
  63. Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol 2016;11:22. https://doi.org/10.1186/s13014-016-0597-7
  64. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. https://doi.org/10.1056/NEJMoa0708857
  65. Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013;329:109-17. https://doi.org/10.1016/j.canlet.2012.10.024
  66. Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 2013;87:73-80. https://doi.org/10.1016/j.ijrobp.2013.05.012
  67. Brade AM, Ng S, Brierley J, Kim J, Dinniwell R, Ringash J, et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2016;94:580-7. https://doi.org/10.1016/j.ijrobp.2015.11.048
  68. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016;4:51. https://doi.org/10.1186/s40425-016-0156-7
  69. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 2016;13:516-24. https://doi.org/10.1038/nrclinonc.2016.30
  70. Formenti SC. Optimizing dose per fraction: a new chapter in the story of the abscopal effect? Int J Radiat Oncol Biol Phys 2017;99:677-9. https://doi.org/10.1016/j.ijrobp.2017.07.028
  71. Vanpouille-Box C, Formenti SC, Demaria S. Toward precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res 2018;24:259-65. https://doi.org/10.1158/1078-0432.CCR-16-0037
  72. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget 2017;8:41242-55.